IE
IPHA

Israel Englander’s Innate Pharma IPHA Stock Holding History

Israel Englander’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,064
Closed -$12.9K – 6115
2026
Q1 		$12.9K Sell
10,064
-10,244
-50% -$16.7K ﹤0.01% 5525
2025
Q4 		$35.5K Buy
+20,308
New +$39.2K ﹤0.01% 5772
2025
Q3 		– Sell
-11,661
Closed -$20.4K – 6237
2025
Q2 		$20.4K Sell
11,661
-3,665
-24% -$7.44K ﹤0.01% 5679
2025
Q1 		$27.3K Buy
+15,326
New +$29.9K ﹤0.01% 5596
2024
Q2 		– Sell
-10,579
Closed -$30.5K – 6208
2024
Q1 		$30.5K Sell
10,579
-1,423
-12% -$3.73K ﹤0.01% 5762
2023
Q4 		$33.6K Sell
12,002
-34,971
-74% -$86.8K ﹤0.01% 5545
2023
Q3 		$119K Sell
46,973
-2,477
-5% -$7.26K ﹤0.01% 5292
2023
Q2 		$155K Sell
49,450
-12,449
-20% -$38.3K ﹤0.01% 5213
2023
Q1 		$176K Sell
61,899
-9,785
-14% -$31.4K ﹤0.01% 5225
2022
Q4 		$267K Buy
71,684
+57,050
+390% +$130K ﹤0.01% 5167
2022
Q3 		$29K Sell
14,634
-2,222
-13% -$6K ﹤0.01% 6357
2022
Q2 		$46K Sell
16,856
-8,259
-33% -$24K ﹤0.01% 6226
2022
Q1 		$84K Sell
25,115
-29,906
-54% -$110K ﹤0.01% 6224
2021
Q4 		$252K Buy
55,021
+27,903
+103% +$148K ﹤0.01% 5702
2021
Q3 		$167K Sell
27,118
-19,649
-42% -$84.7K ﹤0.01% 6212
2021
Q2 		$155K Sell
46,767
-2,967
-6% -$11.8K ﹤0.01% 6110
2021
Q1 		$214K Sell
49,734
-4,963
-9% -$22.2K ﹤0.01% 5458
2020
Q4 		$224K Sell
54,697
-17,960
-25% -$80K ﹤0.01% 4744
2020
Q3 		$288 Hold
72,657
– – ﹤0.01% 3868
2020
Q2 		$530K Hold
72,657
– – ﹤0.01% 3369
2020
Q1 		$485K Sell
72,657
-1,585
-2% -$10.7K ﹤0.01% 2896
2019
Q4 		$477K Buy
+74,242
New +$456K ﹤0.01% 3411

Other funds holding IPHA

LPC
Lion Point Capital New York $20.9M AUM 195.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SP
SmartHarvest Portfolios Poulsbo, Washington $309M AUM
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Israel Englander's IPHA Position: Q2 2026 in Review

Israel Englander sold out of Innate Pharma (IPHA) in Q2 2026, closing a stake of 10,064 shares — an estimated $12.9K sold.

Israel Englander first reported a position in IPHA in Q4 2019 and held it in 22 quarters. The position peaked at $530K in Q2 2020. 10 funds tracked by Wall St. Rank hold IPHA as of Q2 2026.

  • Israel Englander reported no remaining Innate Pharma position as of Q2 2026 after selling out during the quarter.
  • Israel Englander sold 10,064 Innate Pharma shares in Q2 2026, an estimated $12.9K.
  • Israel Englander first reported a position in Innate Pharma in Q4 2019 and held it in 22 quarters.
  • Israel Englander's Innate Pharma position peaked at $530K in Q2 2020.
  • 10 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2026.

Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.